Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Autor: Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group

Publikováno v: Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5

Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5

Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.

Autor: Patrick-Smith M; Medical School, Medical Sciences Division, University of Oxford, UK., Emary K; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Hodgson SH; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Thomas TM; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Te Water Naude R; Medical School, Medical Sciences Division, University of Oxford, UK., Stuart ASV; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Henry J; Medical School, Medical Sciences Division, University of Oxford, UK., English M; Medical School, Medical Sciences Division, University of Oxford, UK., Moore M; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Douglas N; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Pollard AJ; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK., Vanderslott S; Oxford Vaccine Group, University of Oxford and NIHR Oxford Biomedical Research Centre, UK. Electronic address: samantha.vanderslott@paediatrics.ox.ac.uk.

Publikováno v: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126391. Date of Electronic Publication: 2024 Oct 01.

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Autor: Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: robert.shaw@paediatrics.ox.ac.uk., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Andrews NJ; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK., Cameron JC; Public Health Scotland, Glasgow, Scotland, UK., Charlton S; UK Health Security Agency, Porton Down, Salisbury, UK., Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Collins AM; Liverpool School of Tropical Medicine, Liverpool, UK., Darton T; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, UK., Dinesh T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Duncan CJA; The Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; Translational and Clinical Research Institute, Newcastle University, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ferreira DM; Liverpool School of Tropical Medicine, Liverpool, UK., Finn A; Schools of Population Health Sciences and Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Goodman AL; Department of Infection & NIHR BRC, Guy's and St Thomas' NHS Foundation Trust, UK; MRC Clinical Trials Unit, University College London, UK., Green CA; NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; School of Chemical Engineering, University of Birmingham, UK., Hallis B; UK Health Security Agency, Porton Down, Salisbury, UK., Heath PT; The Vaccine Institute, St. George's University of London, London, UK., Hill H; Liverpool School of Tropical Medicine, Liverpool, UK., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Lillie PJ; Infection Research Group, Hull University Teaching Hospitals NHS Trust, Hull, UK., Morey E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Payne R; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, UK., Plested EL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Provstgaard-Morys S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ramsay M; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Screaton GR; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Singh N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Turner DPJ; University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK., Turner PJ; National Heart & Lung Institute, Imperial College London, London, UK., White R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Nguyen-Van-Tam JS; Unit of Lifespan and Population Health, University of Nottingham School of Medicine, Nottingham, UK., Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Snape MD; Oxford NIHR - Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Publikováno v: The Journal of infection [J Infect] 2023 Jun; Vol. 86 (6), pp. 574-583. Date of Electronic Publication: 2023 Apr 06.

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Autor: Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Department of Infection, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: robert.shaw@paediatrics.ox.ac.uk., Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Department of Infection, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Andrews NJ; Immunisation and Countermeasures Division, National Infection Service, UK Health Security Agency, London, UK; 3Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK., Cameron JC; Public Health Scotland, Glasgow-Edinburgh, Scotland, UK., Charlton S; UK Health Security Agency, Porton Down, Salisbury, UK., Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Collins AM; Liverpool Vaccine Group, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Dinesh T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ferreira DM; Liverpool Vaccine Group, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Finn A; Bristol Vaccine Centre, Schools of Population Health Sciences and Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Green CA; NIHR-Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Hallis B; UK Health Security Agency, Porton Down, Salisbury, UK., Heath PT; The Vaccine Institute, St George's University of London, London, UK., Hill H; Liverpool Vaccine Group, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK., Lazarus R; North Bristol NHS Trust, Bristol, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Long F; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Plested EL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Morey ER; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Provstgaard-Morys S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Department of Infection, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ramsay M; Immunisation and Countermeasures Division, National Infection Service, UK Health Security Agency, London, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Screaton GR; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK., Singh N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Turner DPJ; School of Life Sciences, University of Nottingham, and Department of Microbiology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Turner PJ; National Heart & Lung Institute, Imperial College London, London, UK., Vichos I; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Walker LL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., White R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Nguyen-Van-Tam JS; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford NIHR-Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2022 Nov; Vol. 10 (11), pp. 1049-1060. Date of Electronic Publication: 2022 Jun 09.